The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

BACKGROUND: Synapse damage and loss are fundamental to the pathophysiology of Alzheimer’s disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical development approaches for AD therapeutics that can demonstrate reduction of syn...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Alzheimers Res Ther
Autori principali: Colom-Cadena, Martí, Spires-Jones, Tara, Zetterberg, Henrik, Blennow, Kaj, Caggiano, Anthony, DeKosky, Steven T., Fillit, Howard, Harrison, John E., Schneider, Lon S., Scheltens, Phillip, de Haan, Willem, Grundman, Michael, van Dyck, Christopher H., Izzo, Nicholas J., Catalano, Susan M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7053087/
https://ncbi.nlm.nih.gov/pubmed/32122400
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-020-00588-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi